A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Clinical trial NCT01290549 · COMPLETED

Trial details

NCT number: NCT01290549
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia

Start date: 2011-03-22
Primary completion: 2012-06-29
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.